Diagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Fulgent Genetics Inc
FLGT
Current price
$21.26
A technology-driven genetics company offering a broad suite of tests. Its comprehensive testing platform and bioinformatics capabilities make it a pot...
A technology-driven genetics company offering a broad suite of tests. Its comprehensive testing platform and bioinformatics capabilities make it a potentially attractive target for a larger diagnostics or life sciences company looking to expand its genetic testing menu.
QUIDELORTHO CORP
QDEL
Current price
$25.93
A major provider of rapid diagnostic testing solutions. Following its merger with Ortho Clinical Diagnostics, its expanded portfolio in point-of-care ...
A major provider of rapid diagnostic testing solutions. Following its merger with Ortho Clinical Diagnostics, its expanded portfolio in point-of-care and immunoassay testing could be of interest to a strategic buyer seeking scale and diversification.
Exact Sciences Corporation
EXAS
Current price
$45.60
Known for its non-invasive colorectal cancer screening test, this company is a leader in early cancer detection. Its strong brand recognition and pipe...
Known for its non-invasive colorectal cancer screening test, this company is a leader in early cancer detection. Its strong brand recognition and pipeline of diagnostic products for other cancers could make it a prime target for a large pharmaceutical or healthcare company.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Recent unsolicited takeover bids in the diagnostics sector suggest smaller specialized companies may be undervalued. As healthcare consolidation accelerates, firms with innovative technologies in areas like molecular diagnostics, genetic sequencing, and at-home testing look particularly attractive to larger players seeking growth.
What You Need to Know
This is a tactical, event-driven opportunity focused on small to mid-cap diagnostic companies. When one company receives a takeover offer, it often triggers a sector-wide re-evaluation as investors look for the next potential target with similar valuable technological assets.
Why These Stocks
These companies were specifically selected because they possess unique technological capabilities, established market presence, and innovative testing solutions. Each represents a potential acquisition target for larger healthcare conglomerates looking to expand their diagnostic portfolios.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+87.94%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 87.94% over the next year.
Stocks Rated Buy by Analysts
10 of 14 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Hidden Value Waiting to Be Discovered
Recent takeover activity suggests these diagnostic companies may be significantly undervalued. Their innovative technologies could be worth much more to potential acquirers than current market prices suggest.
Potential Overnight Price Jumps
When acquisition offers are announced, target company stocks often surge dramatically. Being invested before a takeover bid is announced could mean substantial quick gains if a company becomes the next target.
Industry Experts Are Already Moving
The OraSure takeover bid signals that industry insiders see tremendous value in diagnostic technologies. Smart money is already positioning for more consolidation in this rapidly evolving healthcare sector.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Uncle Sam's Semiconductor Stake
The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.
The Cybersecurity Consolidation Wave
Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.
American Chipmakers: A Tariff-Driven Shift
President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.
Frequently Asked Questions
Everything you need to know about the product and billing.